Qin Gang, Li Xianfeng, Chen Zilong, Liao Guangcha, Su Yu, Chen Yaode, Zhang Wei
Department of Neurosurgery, The First People's Hospital of Nanning, Nanning, 530022, China.
Department of Neurology, The First People's Hospital of Nanning, Nanning, 530022, China.
Mol Neurobiol. 2017 Jul;54(5):3264-3270. doi: 10.1007/s12035-016-9878-2. Epub 2016 Apr 18.
YKL-40 is the most highly expressed gene in glioblastoma compared with normal brain tissues. Previous studies assessing the association between YKL-40 and survival in glioblastoma patients reported varying magnitude of estimates. The objective of this meta-analysis was to determine the prognostic value of YKL-40 in glioblastoma patients. PubMed and Embase databases were searched for studies relating to YKL-40 and prognosis of glioblastoma patients. Studies reporting estimates for overall survival by YKL-40 expression in glioblastoma patients were considered eligible. A meta-analysis of included studies was performed using fixed- or random-effect model to calculate the pooled hazard ratio (HR) and 95 % confidence interval (95%CI). Eight studies were ultimately considered eligible and included into the meta-analysis. Those eight studies included 1241 glioblastoma patients. Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001). Meta-analysis of studies with adjusted estimates and high quality showed that high YKL-40 expression was independently associated with worse overall survival in glioblastoma patients (HR = 1.50, 95%CI 1.35-1.66, P < 0.001). Both subgroup analysis and sensitivity analysis validated the obvious association between high YKL-40 expression and worse overall survival in glioblastoma patients. High YKL-40 expression is independently and markedly associated with worse overall survival in glioblastoma patients. YKL-40 is a good predictive biomarker of prognosis in glioblastoma patients.
与正常脑组织相比，YKL-40是胶质母细胞瘤中表达最高的基因。先前评估YKL-40与胶质母细胞瘤患者生存率之间关联的研究报告的估计值大小不一。这项荟萃分析的目的是确定YKL-40在胶质母细胞瘤患者中的预后价值。在PubMed和Embase数据库中检索与YKL-40和胶质母细胞瘤患者预后相关的研究。报告胶质母细胞瘤患者中YKL-40表达对总生存期估计值的研究被认为符合要求。使用固定效应或随机效应模型对纳入研究进行荟萃分析，以计算合并风险比（HR）和95%置信区间（95%CI）。最终有八项研究被认为符合要求并纳入荟萃分析。这八项研究共纳入1241例胶质母细胞瘤患者。对这些研究的荟萃分析表明，YKL-40高表达与胶质母细胞瘤患者较差的总生存期相关（HR = 1.46，95%CI 1.33 - 1.61，P < 0.001）。对经过调整估计值且质量较高的研究进行的荟萃分析表明，YKL-40高表达与胶质母细胞瘤患者较差的总生存期独立相关（HR = 1.50，95%CI 1.35 - 1.66，P < 0.001）。亚组分析和敏感性分析均证实了YKL-40高表达与胶质母细胞瘤患者较差的总生存期之间存在明显关联。YKL-40高表达与胶质母细胞瘤患者较差的总生存期独立且显著相关。YKL-40是胶质母细胞瘤患者预后的良好预测生物标志物。
